Gondo et al, Growth Hormone-Releasing Peptide-2 Stimulates GH Secretion in GH-Deficient Patients with Mutated GH-Releasing Hormone Receptor, The Journal of Clinical Endocrinology & Metabolism, Volume 86, Issue 7, 1 July 2001, Pages 32793283, Mericq V, Cassorla F, Salazar T, Avila A, Iiguez G, Bowers CY, Merriam GR
I hope you find my analysis more balanced if not as provocative as his
Pramlintide, the first generation (1990s) In the 1990s, the pharmaceutical company Amylin Pharmaceuticals developed Pramlintide , a modified amylin with three proline substitutions at positions 25, 28 and 29
This matters for this comparison because Ros published Ro Body Program materials reference 15% average body weight reduction at week 68 a figure from the STEP clinical trial program, which studied branded Wegovy, not compounded semaglutide